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Abstract 
Objectives 
In the presence of a chronically occluded coronary artery, the collateral circulation 
matures by a process of arteriogenesis, however there is considerable variation between 
individuals as to the functional capacity of that collateral network. This could be explained 
by differences in endothelial health and function. We endeavoured to examine the 
relationship between functional extent of collateralisation and levels of biomarkers which 
have been shown to relate to endothelial health. 
Methods 
We measured four potential biomarkers of endothelial health in 34 patients with 
mature collateral networks who underwent successful percutaneous coronary intervention 
(PCI) to a chronic total coronary occlusion (CTO) prior to PCI and 6-8 weeks post-PCI and 
examined the relationship of biomarker levels with physiological measures of 
collateralisation.  
Results 
We did not demonstrate a significant change in systemic levels of sICAM-1, sE-
selectin, microparticles or tissue factor 6-8 weeks after PCI. We did demonstrate an 
association between estimated retrograde collateral flow prior to CTO recanalization and 
lower levels of sICAM-1 (r=0.39,p=0.026), sE-selectin (r=0.48, p=0.005) and microparticles 
(r=0.38, p=0.03).  
Conclusions 
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Recanalization of a CTO and resultant regression of a mature collateral circulation 
does not alter systemic levels of sICAM-1, sE-selectin, microparticles or tissue factor. The 
identified relationship of retrograde collateral flow with sICAM-1, sE-selectin and 
microparticles is likely to represent an association with an ability to develop collaterals 
rather than their presence and extent.  
 
Condensed abstract 
The functional capacity of collateral networks between patients with CTOs varies 
considerably. This could be explained by differences in endothelial health and function. Four 
potential biomarkers of endothelial health were measured in 34 patients with mature 
collateral networks who underwent successful PCI to a CTO prior and the relationship 
between biomarker levels with physiological measures of collateralisation was examined. 
We found no significant change in systemic levels of sICAM-1, sE-selectin, microparticles or 
tissue factor when baseline measures were compared with those at follow-up. We did find 
an association between estimated retrograde collateral flow prior to CTO recanalization and 
lower levels of sICAM-1, sE-selectin and microparticles. Regression of a mature collateral 
circulation does not alter systemic levels of sICAM-1, sE-selectin, microparticles or tissue 
factor. Any relationship of retrograde collateral flow with sICAM-1, sE-selectin and 
microparticles is likely to represent an association with an ability to develop collaterals 
rather than their presence and extent.  
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Introduction 
In response to  a chronically occluded coronary artery, coronary collaterals develop 
which supply the myocardium distal to the occlusion and are often sufficient to preserve 
resting left ventricular systolic function in spite complete coronary occlusion1,2. Our current 
understanding is that growth of a network of pre-existing anastamotic arterioles, termed 
arteriogenesis, occurs independently of an ischaemic stimulus by means of mechanical 
transduction of endothelial shear stress, stimulating a cascade of growth factors and 
inflammatory mediators3. However there is considerable variability to the extent of 
functional collateral supply that individuals develop4. A number of studies have suggested 
associations between biomarkers thought be involved in the arteriogenic process and 
functional collateralisation5–10. However the significance of any difference in biomarkers 
levels between individuals with ‘good’ and ‘poor’ functional collateralisation is not clear. 
Any identified associations may reflect a direct relationship between extent of 
collateralisation and the biomarker in question, a relationship between biomarker levels and 
endothelial or circulatory health, or a relationship with active arteriogenic activity (which 
could mean biological factors active in the process could be higher in individuals with less 
well developed or less well matured collateral circulations).  
Both ICAM-1 and E-selectin have been implicated in the arteriogenic process5,11,12. 
Microparticles are thought to play an important role in endothelial function, and may relate 
to endothelial health13, and tissue factor  has been shown in vitro to be involved in the 
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regulation of both endothelial14 and smooth muscle cell15 proliferation, both of which are 
thought to be integral to the arteriogenic process. 
  We endeavoured to investigate the relationship of these four potential biomarkers 
with indices of collateral flow, resistance and functional collateralisation in a population 
undergoing successful PCI to a CTO, all with well established collateral networks. Serum 
biomarkers were measured at the time of the procedure and at follow-up to investigate the 
effect of the presence of an active collateral network on biomarker levels. 
 
Methods 
Study patients  
Thirty four patients who underwent successful PCI to a CTO for symptoms of angina 
(Canadian Cardiovascular Society (CCS) class 1-3) were recruited consecutively in a single 
tertiary centre between January 2013 and June 2014. A CTO was defined as complete 
coronary occlusion of ≥3 months duration with TIMI grade 0 flow16. Exclusion criteria were 
inability to provide consent, >1 occluded vessel, prior CABG with any patent grafts, left main 
stem stenosis considered to be haemodynamically significant and contra-indications to 
adenosine. All included patients had right dominant coronary anatomy. The presence of 
viable myocardium in the CTO territory was confirmed in all patients by myocardial 
perfusion scintigraphy(n=26, 76.5%), dobutamine stress echocardiography(n=1, 2.9%) or by 
the absence of a wall motion abnormality by echocardiography or left ventricular 
angiography without additional confirmation(n=7, 20.6%).  Patient’s usual medications were 
continued and they were asked to abstain from caffeine for 48 hours prior to the procedure. 
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Ethics 
The study protocol was approved by the local research ethics committee 
(12/YH/0360). All subjects provided written informed consent. 
Catheter laboratory protocol 
Dual arterial access was used for all procedures. Femoral venous access was 
obtained for central administration of adenosine and measurement of central venous 
pressure(CVP) at the beginning and end of the procedure using a catheter positioned in the 
right atrium.  
Before PCI, and at the end of the procedure, 20ml of blood was aspirated from the 
catheter in the right atrium. At the same time as the pre-PCI right atrial sampling, 20ml of 
blood was aspirated from the femoral arterial sheath. At follow-up, 6-8 weeks after the 
successful procedure, 20ml of blood was sampled from a peripheral vein.  
After initial blood sampling, patients were anti-coagulated with 100 U/kg of 
unfractionated heparin to maintain an activated clotting time of >300 seconds. A 200mcg 
bolus of intra-coronary glyceryl trinitrate(GTN) was given and iso-centred coronary 
angiograms of both non-target vessels were taken.  
The haemodynamic assessment protocol has been described previously17. Briefly, a 
dual sensor pressure-velocity 0.014” intracoronary wire (Combowire, Volcano Corp, San 
Diego, CA)18 was connected to a ComboMap console (Volcano Corp) and used for 
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haemodymamic measurements. In order to estimate absolute coronary flow in the non-
target vessels, the wire was advanced to the segment of the non-target vessel proximal to 
any major side-branches and manipulated to obtain a good Doppler trace. After 
administration of 100mcg intra-coronary GTN, once the hyperaemic response had settled, 
continuous recordings from the ComboMap were taken. Samples were recorded at 200Hz 
and stored on disk for offline analysis. 
PCI of the CTO was undertaken at the discretion of the treating interventional 
cardiologist using an antegrade or retrograde approach. Once access to the vessel lumen 
distal to the point of occlusion was achieved, prior to restoration of antegrade flow, a 
microcatheter was placed into the distal vessel to facilitate delivery of the Combowire. The 
wire was normalised to aortic pressure at the tip of the catheter, alongside the 
microcatheter, removed and advanced through the microcatheter to the distal segment of 
each non-target vessel and manipulated to obtain a good Doppler trace. After 
administration of 100mcg intra-coronary GTN, once the hyperaemic response had settled, 
continuous recordings from the ComboMap were taken. Hyperaemia was achieved by 
central venous administration of adenosine at 140 mcg/kg/minute. Once steady state 
hyperaemia had been reached and a continuous recording of >20 beats taken, adenosine 
infusion was ceased. Samples were recorded at 200Hz and stored on disk for offline analysis. 
 PCI success was defined as stenting of the target vessel with <30% residual stenosis 
and thrombolysis in myocardial infarction (TIMI) grade III flow. After successful PCI, non-
target and target vessel haemodynamic measurements were repeated as described pre-
procedure, at the site of the previous measurement.  
Recorded data was analysed using dedicated custom software (Study Manager, 
Academic Medical Center, University of Amsterdam, The Netherlands) 
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Angiographic assessment 
Proximal non-target vessel diameters (at the point of proximal haemodynamic 
measurement) measured in two orthogonal views were calculated by two independent 
observers using quantitative coronary angiography(QCA)(GE Centricity CA1000, GE 
Healthcare) using the guiding catheter luminal diameter as reference. Mean values from 
both observers were used for analysis. The vessel collateral connection(CC) grade19 and 
modified Rentrop score20 were assessed by two independent observers blinded to 
haemodynamic measurements and agreed by consensus.  
 
Data analysis 
Fractional collateral flow reserve was calculated as (Pd-CVP)/Pa-CVP), using mean 
pressures taken over 5 cardiac cycles at stable hyperaemia21, with Pd measured in the occluded 
segment of the artery, prior to restoration of antegrade flow22. Collateral flow velocity reserve was 
calculated with flow velocities in the occluded segment measured at rest and steady state 
hyperaemia23 as APV at steady state hyperaemia divided by APV at baseline, measured over 5 
cardiac cycles. The resistance index of the collateral supply pathway, incorporating both the 
resistance of the collateral vessel and of the donor segment proximal to the collateral take-
off was calculated as: RColl=(PAo-Pd)/APVd (mmHg · cm-1 · s-1)6,24. The peripheral resistance 
index, or the resistance in the target (collateral recipient) vessel downstream of the 
collateral supply was calculated as:  RP=Pd/APVd (mmHg · cm-1 · s-1)6,24.  
The difference in combined non-target vessel absolute flow before and after 
successful CTO PCI should approximate to absolute flow through the retrograde collateral 
network (although would not include the contribution of antegrade bridging collaterals).For 
the purposes of estimating non-target vessel flow, absolute coronary flow was estimated as 
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(πx proximal vessel radius2)x(proximal vessel APV/2)25,26. As resting absolute myocardial 
blood flow is closely related to rate pressure product(RPP), values for resting absolute 
coronary flow were divided by the respective RPP/10,00027.  
 
Biomarker assays 
For the measurement of sICAM-1 and sE-selectin, blood samples were drawn into 
serum separator tubes, allowed to clot for 30 minutes prior to centrifugation and 
centrifuged for 15 min at 1000g. The separated serum was stored in aliquots at −80°C to 
permit assay in batches. The concentration of sE-Selectin and sICAM-1 were determined 
using a commercially available specific sandwich enzyme-linked immunosorbent assay 
(ELISA) kit (Quantikine, R&D Systems). Briefly, ELISA plates pre-coated with a specific 
capture antibody were used, standards and samples were added to the plate and incubated 
for 2 hours at room temperature. The bound soluble adhesion molecule of interest was 
detected by a further 2 hour incubation with a specific antibody conjugated to horseradish 
peroxidise followed by a 30 minute incubation with stabilized hydrogen peroxide and 
tetramethylbenzidine. The reaction was stopped by the addition of 2 N sulphuric acid to 
each well and the optical density at 450nm measured using a microplate reader (BMG 
Labtech, Aylesbury, United Kingdom).   
 For the measurement of plasma microparticles blood samples were drawn into 
vacutainer tubes containing 0·11 mol/l sodium citrate, centrifuged for 15 minutes at 1,500g 
at room temperature. Plasma supernatant was then rapidly centrifuged for 2 minutes at 
13,000g. The separated ‘platelet free’ plasma was stored in aliquots at −80°C to permit 
assay in batches. Microparticles concentrations were determined using a commercially 
available specific ELISA kit (ZYMUPHEN MP-Activity, Hyphen BioMed, Quadratech, Epsom, 
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United Kingdom). Briefly, the diluted plasma sample or standard, supplemented with 
calcium, Factor Xa and thrombin inhibitors was added to a microplate pre-coated with 
Streptavidine and biotinylated Annexin V and incubated  at 37°C for 1 hour. After a washing 
step, a Bovine factor Xa-Va mixture containing calcium and purified human Prothombin are 
added to each well and incubated for a further 10 minutes at 37°C. Thrombin specific 
chromogenic substrate was then added to each well, after 3 minutes 2% Citric acid was 
added as a stop solution to each well and optical density at 405nm measured using a 
microplate reader (BMG Labtech).   
 For the measurement of plasma TF levels, blood samples were drawn into vacutainer 
tubes containing 0·11 mol/l sodium citrate, centrifuged for 15 minutes at 3,000g and stored 
in aliquots at −80°C to permit assay in batches. TF was measured by ELISA. Briefly, microtitre 
ELISA plates were coated overnight with a specific TF capture antibody (sheep anti-Human 
Tissue Factor, Enzyme Research Laboratories, Swansea, United Kingdom) in 50 mmol 
carbonate buffer pH = 9.6. The plates were then incubated overnight at  4°C with 
PBS/Bovine serum albumen blocking buffer. After a washing step, standards (diluted 
recombinant tissue factor, American Diagnostica inc, Stanford, USA) and samples were 
added to the plate and incubated for 90 minutes at room temperature. After another 
washing step, anti-TF IgG conjugated to horseradish peroxidise was added to the plates and 
incubated for 90 minutes at room temperature. The plates were washed again and a 
tetramethylbenzidine substarte solution added and agitated at room temperature for 15 
minutes. The reaction was stopped by the addition of 2 M sulphuric acid to each well and 
the optical density at 490nm measured using a microplate reader (BMG Labtech). 
The intra-assay coefficient of variation of the ELISA measurements was 9.2% for 
sICAM-1, 9.3% for sE-Selectin, 9.5% for microparticles and 13.8% for TF. Inter-assay 
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coefficients were 7.1% for sICAM-1, 12.9% for sE-Selectin, 11.6% for microparticles and 
14.7% for TF. 
 
 
Biomarker comparsions and correlations 
 To establish if biomarkers levels in the right atrium were elevated relative to sample 
sites remote from the heart, right atrial biomarker levels were compared with levels taken 
from the femoral arterial sheath prior to PCI. To investigate if there had been a change in 
biomarker levels between prior to PCI and follow-up, right atrial biomarker levels taken 
prior to PCI were compared with those from a peripheral venous sample taken at follow-up. 
Correlations were tested between right atrial biomarker levels and FFRcoll, CollFVR, the 
change in non-target baseline flow after PCI (Δcombined non-target vessel baseline flow, an 
approximation of retrograde collateral flow after PCI), RColl and RP. 
Statistical analysis 
 
Stata v.12(StataCorp) was used for statistical analysis. Continuous values are 
expressed as means±SD, or median(25th percentile-75th percentile) as appropriate. 
Continuous variables were compared using a paired t-test or Wilcoxon signed-rank test. 
Correlations were quantified using Pearson’s correlation coefficient. Probability values were 
2-sided, and values of p<.05 considered significant. 
 
Results 
12 
 
Pre-procedural biomarker levels were taken in all 34 successful cases, follow-up 
levels were taken at between 6 and 8 weeks post PCI in 30. Drug-eluting stents were used 
for all procedures. Demographics, angiographic and procedural details are shown in Table 1.  
 
 
 
Haemodynamic measures of functional collateralisation  
 Table 2 lists summary statistics for measures of functional collateralisation, collateral 
flow and resistance. Measures of collateral perfusion are only included if the vessel distal to 
the occlusion was accessed antegradely (n=28). As one of those patients had inadequate 
flow traces, combined pressure and flow measurements taken distal to the occlusion are 
only included in 27 patients. Pre and post PCI donor vessel flow measurements were 
possible in 32 of 34 patients. Mean combined absolute baseline flow in both non-target 
vessels, adjusted for rate pressure product reduced from 335.0 ml· min-1 prior to PCI to 
281.3 ml· min-1 post-PCI (difference -53.8 ml· min-1, 95% CI -93.9 to -13.6, p=.01). Mean 
combined absolute hyperaemic flow in both non-target vessels reduced from 580.8 ml· min-
1 prior to PCI to 543.6 ml· min-1 post-PCI (difference -37.2 ml· min-1, 95% CI -75.5 to 0.1, 
p=0.056).   
 
Biomarker levels 
 Levels of all four measured biomarker levels are depicted in figure 1. We found no 
veno-arterial gradient in levels of any of the biomarkers. Biomarker levels taken at follow up 
from a peripheral vein were also not significantly different from arterial samples taken 
immediately prior to PCI when the collateral pathway was still ‘active’.  
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 Figure 2 shows the relationship between pre-procedural right atrial biomarker levels 
and measures of collateral perfusion. Although we did not demonstrate a relationship 
between any of the biomarkers and measures of collateralisation taken distal to the point of 
occlusion prior to recanalization, we did demonstrate a significant correlation between the 
change in baseline non-target vessel flow and levels of sICAM-1, sE-selectin and 
microparticles. We found no correlation between any biomarker and measures of collateral 
pathway resistance Rcoll (sICAM-1 r=0.10, p=0.57; sEselectin r=0.14, p=0.46; microparticles 
r=0.16, p=0.39; TF r=-0.06, p=0.75) or the resistance of  the collateral recipient vessel 
downstream of the collateral supply RP (sICAM-1 r=0.09, p=0.65; sEselectin r=-0.18, p=0.33; 
microparticles r=0.09, p=0.64; TF r=-0.15, p=0.44). 
  
Discussion 
In a population with established extensive collateral networks, with a median 
duration of coronary occlusion in excess of 1 year, we demonstrate no significant reduction 
in systemic sICAM-1, sE-selectin, microparticle or TF levels at 6-8 weeks after CTO 
recanalization. We have also not demonstrated a gradient in levels of these biomarkers 
between the right atrial and femoral arterial circulation when the collateral network was 
still present and ‘active’. In addition, we have found no association between established 
guidewire based indices of collateral perfusion (FFRcoll and CollFVR) and biomarker levels. 
We have however demonstrated an association between change in summed non-target CTO 
vessel flow and levels of sICAM-1, sE-selectin and microparticles, which is likely to represent 
an association between retrograde collateral absolute flow prior to CTO recanalization and 
each biomarker. 
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The absence of a veno-arterial gradient  
We found no significant difference in any biomarker levels if they were sampled in 
the right atrium compared with samples taken remote from the heart through the femoral 
arterial sheath. This suggests peripherally taken samples at follow up are representative of 
levels in the right atrium. A limitation of the current study is that we did not take samples 
from the coronary sinus, or beyond the occluded segment. It is possible that levels of 
biomarkers taken in this way may have been higher than in the systemic circulation.  
 
No reduction in biomarker levels at follow-up  
In previous studies which have demonstrated relationships between collateral 
perfusion (whether functional or angiographic) and biomarker levels5–10, including some of 
the biomarkers measured here5, a more heterogeneous patient population was included 
than in this study. In those studies which included patients with non-occlusive disease, 
lesions of differing physiological severity must have been included5,7–10. A difference in basic 
fibroblast growth factor has been identified in coronary occlusions of <3 months duration 
compared with those of ≥3 months in duration (what we would now consider to be a 
CTO16). It is conceivable that other growth factors implicated in the arteriogenic process 
might show a similar relationship with duration of occlusion. The population included in this 
study all had a well developed collateral circulation with Rentrop grade 2-3 and CC grade 1-2 
angiographic collateralisation in all patients and coronary occlusion which had been present 
for at least 3 months (median 53 weeks). If biomarker levels related directly to extent of 
collateralisation, then one would expect that after the chronically occluded vessel is 
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recanalized, that biomarker levels would fall. This was not the case in any of the four 
biomarkers that we measured. 
Extent of collateralisation does not necessarily reflect level of arteriogenic activity. In 
fact, a less well developed collateral circulation may reflect more recent coronary occlusion 
or progression of flow limitation caused by a coronary stenosis. The various differences in 
biochemical activity that have been reported between individuals of differing degrees of 
collateralisation may reflect an active arteriogenic process in the less well collateralised 
patients. Our results, showing no difference in biomarker levels 6-8 weeks after 
recanalization in a population with well established collaterals would be in keeping with, but 
are not necessarily supportive of that hypothesis.  
In ICAM-1 and sE-selectin we chose to investigate two biomarkers which appear to 
have a clear role in arteriogenesis3,12. Both  are involved in the adhesion of macrophages to 
shear-stress activated collateral endothelium, an important step in the arteriogenic process 
and ICAM-1 expression has been shown to be stimulated by increased shear stress11. In 
animal models, arteriogenesis is reduced in the presence of ICAM-1 deficiency12. Both 
sICAM-1 and sE-selectin have been shown to be at higher levels in patients with a lower 
angiographic grade of collateral5. Our finding that their level did not decrease after CTO 
recanalization would suggest that any relationship between extent of collateralisation does 
not relate to the presence of an established collateral circulation, but more likely the ability 
to form one.   
 
Biomarker levels: relationship with collateral flow 
We were unable to demonstrate a relationship between invasively derived measures 
of collateral perfusion and resistance and any of the four biomarkers we tested (figure 2). 
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One might expect functional measures of collateralisation to be more reliable than 
angiographic measures and a relationship therefore easier to identify19. However, the 
number of patients in our study was small and even excluding measures in which the 
collateral dependent vessel was accessed via retrograde collaterals; antegrade access was 
gained by a dissection re-entry approach in a sizeable proportion of patients, which may 
have altered measures of collateral perfusion. Regardless of approach to CTO recanalization, 
collateral flow diminishes rapidly after restoration of antegrade flow22,28. The change in flow 
in the other major epicardial arteries should represent an approximation of retrograde 
collateral flow in the presence of a CTO. Given the limitations of multiple testing, the 
correlations that we have identified between change in donor vessel flow and levels of 
sICAM-1, sE-Selectin and microparticles can only be viewed as hypothesis generating. 
Nevertheless, the presence of a similar correlation between three of the four biomarkers 
that we have studied is interesting and is consistent with previous published findings5. 
 
Markers of endothelial health: a possible explanation 
Arteriogenesis is a complex, endothelium dependent process and it is perhaps too 
much to expect a single biomarker to reflect arteriogenic activity or capacity. The levels of 
biomarkers that we have investigated have all been shown to be related to what could be 
considered to be endothelial health14,29–33, lower levels of each being associated with a 
more ‘healthy endothelium’. Angiographic extent of collateralisation has previously been 
shown to be associated with endothelial function in recanalized segments of CTOs34. This 
may well extend to an association between global coronary (and possibly systemic) 
endothelial health and the ability for collateral maturation. The various studies (including 
this one) which have demonstrated an association between various biomarkers levels and 
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extent of collateralisation, may be indirectly describing the same link between endothelial 
health and arteriogenic capacity.   
 
Limitations  
This is a single centre study, with a small number of patients. However, the 
population all had well developed collateral networks and we made comparison to 
biomarker levels both in the presence and absence of a collateral network supplying an 
occluded coronary segment and also to coronary haemodynamics associated with that 
change.  
It is possible that biomarker levels taken from the coronary sinus or occluded 
coronary segment (through a microcatheter) may have been higher than in the right atrium 
or systemic circulation. However a number of studies have related systemic levels of 
biomarker to collateral development5,8–10, so these measures remain pertinent. In addition, 
without systemic measures of biomarkers, it would not have been possible to take samples 
at follow-up for comparison. 
An important limitation is that we tested for biomarker correlations with multiple 
physiological indices and these correlations should therefore be interpreted with caution. 
The significant correlations we have identified are related to one another however and have 
a plausible unifying biological explanation. Finally, our estimate of retrograde collateral flow 
ignores any antegrade bridging collaterals; this might have resulted in an underestimation of 
collateral flow in some patients. 
 
Conclusions 
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In patients with established collateral circulations supplying viable myocardium distal 
to CTOs, systemic levels of ICAM-1, sE-selectin, microparticles and TF do not reduce at 
follow up after recanalization of the CTO. Levels of ICAM-1, sE-selectin, microparticles are 
related to estimated total retrograde collateral flow prior to recanalization, which is most 
likely explained by an association with the ability to develop a collateral supply.  
A possible biological explanation is that those with greater endothelial health have a 
greater capacity for arteriogenesis, however further studies would be required to examine 
this hypothesis further. 
Tables 
Table 1. Baseline Characteristics, Angiographic, and Procedural Details 
Demographics(n=34)  
Male, n(%) 27(79.4) 
Age 60.8±9.6 y 
Left ventricular ejection fraction(%) 56.2±11 
Estimated occlusion duration(weeks) 53(30-104) 
CCS class I/II/III/IV 8/20/6/0 
Previous PCI, n(%) 9(26.5) 
Previous myocardial infarction, n(%) 10(29.4) 
Hypertension, n(%) 6(17.7) 
Diabetes Mellitus, n(%) 5(14.7) 
Current smoker, n(%) 10(29.4) 
Angiographic details  
CTO vessel(RCA/LCx/LAD) 21/4/9 
Rentrop collateral grade(1/2/3) 0/12/22 
Maxiumum CC grade(0/1/2) 0/18/16 
Procedural details 
 
 
Number of stents 1/2/3/4/5 6/11/10/6/1 
 
Length of stent(mm) 74.5(44-101) 
 
Means of recanalization 
 
 
Antegrade lumen-lumen, n(%) 
 
19(55.9)
Antegrade dissection re-entry, n(%) 9(26.5) 
Retrograde lumen-lumen, n(%) 3(8.8) 
Retrograde dissection re-entry, n(%) 3(8.8) 
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PCI indicates percutaneous coronary intervention; ACE-inhibitor, angiotensin converting 
enzyme inhibitor; ARB, angiotensin II receptor blocker; RCA, right coronary artery; LCx, 
left circumflex artery; LAD, left anterior descending artery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Haemodynamic measures of functional collateralisation 
FFRcoll* 0.38±0.12 
CollFVR† 1.07±0.25 
RColl† 
(mmHg · cm-1 · s-1) 
4.87 (2.82-7.04) 
RP† 
(mmHg · cm-1 · s-1) 
4.85 (3.71-6.66) 
RColl Hyperaemia† 
(mmHg · cm-1 · s-1) 
4.94 (2.88-7.77) 
RP Hyperaemia† 
(mmHg · cm-1 · s-1) 
3.39 (2.09-5.26) 
Δcombined non-target vessel baseline flow§ 
(ml· min-1) 
-53.7±117.8 
Δcombined non-target vessel hyperaemic flow§ 
(ml· min-1) 
-37.2±106.0 
*n=28, †n=27, §n=32; FFRcoll indicates Fractional collateral flow reserve; CollFVR, collateral 
flow velocity reserve; RColl, resistance of the collateral vessel; RP, resistance in the collateral 
recipient vessel downstream of the collateral supply.  
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Figures 
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Figure 1. Comparison of right atrial with femoral arterial biomarker levels pre-PCI, and pre-
PCI biomarker levels (Femoral arterial) with levels at follow-up (peripheral venous). Top 
left: sICAM-1, top right: sE-Selectin, bottom left: microparticles, bottom right: tissue factor 
(TF). 
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Figure 2. Relationships between biomarkers levels measured in the right atrium prior to 
PCI: sICAM-1,  sE-Selectin, microparticles and tissue factor (TF); and measures of collateral 
perfusion: fractional collateral flow reserve(FFRcoll, n=31), Collateral flow velocity reserve 
(CollFVR, n=30), and  summed change in absolute baseline flow, adjusted for rate 
pressure product after CTO PCI (n=32). TF levels are transformed logarithmically. Solid 
markers represent measures taken by a retrograde approach. 
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